Definium Therapeutics, Inc. - Common Shares (NQ:DFTX)

Definium Therapeutics Announces New Employee Inducement Grants

September 28, 2026

Performance

52-Week Range 29.3% below 52-week high

35.16

14.6252W Low 49.7052W High

1 Week

32.021W Low 34.951W High

Definium Therapeutics, Inc. - Common Shares (DFTX) traded between $14.62 and $49.70 over the past 52 weeks and last traded at $35.16, 29.3% below its 52-week high. Over the past week it ranged between $32.02 and $34.95.

Past 12 Months

+2.3%

-10.5%

-17.9%

+51.7%

+128.6%

1W +$0.78

1M -$4.12

3M -$7.64

6M +$11.98

YTD +$19.78

1Y +$19.78

DFTX was +128.6% over the past year, +51.7% over six months, +128.6% year to date, +2.3% in the last week.

12 Months vs Market

DFTX

+128.6%

DIA

+12.2%

SPY

+14.6%

QQQ

+17.6%

IWM

+11.1%

Over the past 12 months DFTX returned +128.6% versus DIA (Dow) +12.2%, SPY (S&P 500) +14.6%, QQQ (Nasdaq 100) +17.6% and IWM (Russell 2000) +11.1%.

Volume & Liquidity 0.47× 3-mo avg

Today 1,006,565 3-mo avg 2.1M

1.8M

2.2M

2.1M

2.5M

YTD

2.2M

DFTX most recently traded 1,006,565 shares against a 3-month average daily volume of 2.1M.

More News

Definium Therapeutics Highlights Phase III DT120 Gains in Anxiety and Depression ↗

September 24, 2026

Definium Therapeutics (NASDAQ:DFTX) Slides After Q2 Loss Misses Estimates on Warrant Charge ↗

August 06, 2026

Via Chartmill

Definium Therapeutics’ DT120 Hits Phase III Goals in Anxiety Study ↗

September 19, 2026

Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder

September 14, 2026

Definium Therapeutics Announces New Employee Inducement Grants

September 14, 2026

Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026

September 13, 2026

Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026

September 10, 2026

Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results

September 08, 2026

Definium Therapeutics Announces New Employee Inducement Grants

August 31, 2026

Definium Therapeutics to Participate at Upcoming Investor Conferences and Events

August 26, 2026

Definium Therapeutics Announces New Employee Inducement Grants

August 17, 2026

Definium Therapeutics’ DT120 Meets Phase III Goals in GAD Study ↗

August 13, 2026

Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder

Wondering what's happening in today's pre-market session? ↗

August 12, 2026

Via Chartmill

August 12, 2026

Definium Therapeutics Q2 Earnings Call Highlights ↗

August 06, 2026

Definium Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

August 06, 2026

A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 Readout

August 05, 2026

From USA News Group

Via GlobeNewswire

Definium Therapeutics Announces New Employee Inducement Grants

August 03, 2026

Definium Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026

July 30, 2026

Definium Therapeutics Announces New Employee Inducement Grants

July 20, 2026

Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology

July 16, 2026

New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)

July 14, 2026

Definium Therapeutics Announces New Employee Inducement Grants

July 06, 2026